Compare AbCellera Biologics Inc (ABCL) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Canadian Natural Resources Ltd. — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Canadian Natural Resources Ltd. trades at $42 (market cap $84.83B). The key difference: Canadian Natural Resources Ltd. is far larger — about 36.1× AbCellera Biologics Inc's market cap, and Canadian Natural Resources Ltd. pays a 4.32% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CNQ | |
|---|---|---|
Market Cap | $2.35B | $84.83B |
Sector | Health | Energy |
52-Week High | $8.12 | $50.55 |
52-Week Low | $2.78 | $29.31 |
Enterprise Value | $1.99B | $96.06B |
Dividend Yield | — | 4.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Canadian Natural Resources (CNQ) trades at $40.69, up 2.65% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows attractive valuation metrics with P/E of 11.8 and robust profitability including 24.5% net margin. Technical indicators signal bearish sentiment despite recent price strength, while analyst consensus remains overwhelmingly positive with 75% buy ratings. Recent dividend declarations and strong cash flow generation support shareholder returns.
CNQ presents a compelling value opportunity with solid fundamentals and positive earnings surprises, though technical weakness and oil price volatility pose near-term risks. The company's strong balance sheet and consistent dividend payments provide downside protection, while operational efficiency and production growth drive long-term potential. Investors should weigh valuation appeal against energy sector cyclicality and technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
